|
1
|
Jain A and Sweet K: Blastic plasmacytoid
dendritic cell neoplasm. J Natl Compr Canc Netw. 21:515–521.
2023.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Garnache-Ottou F, Vidal C, Biichlé S,
Renosi F, Poret E, Pagadoy M, Desmarets M, Roggy A, Seilles E,
Soret L, et al: How should we diagnose and treat blastic
plasmacytoid dendritic cell neoplasm patients? Blood Adv.
3:4238–4251. 2019.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Wilson NR, Konopleva M, Khoury JD and
Pemmaraju N: Novel therapeutic approaches in blastic plasmacytoid
dendritic cell neoplasm (BPDCN): Era of targeted therapy. Clin
Lymphoma Myeloma Leuk. 21:734–740. 2021.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Adimora IJ, Wilson NR and Pemmaraju N:
Blastic plasmacytoid dendritic cell neoplasm (BPDCN): A promising
future in the era of targeted therapeutics. Cancer. 128:3019–3026.
2022.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Pollyea DA, Altman JK, Assi R, Bixby D,
Fathi AT, Foran JM, Gojo I, Hall AC, Jonas BA, Kishtagari A, et al:
Acute myeloid leukemia, version 3.2023, NCCN clinical practice
guidelines in oncology. J Natl Compr Canc Netw. 21:503–513.
2023.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Economides MP, McCue D, Lane AA and
Pemmaraju N: Tagraxofusp, the first CD123-targeted therapy and
first targeted treatment for blastic plasmacytoid dendritic cell
neoplasm. Expert Rev Clin Pharmacol. 12:941–946. 2019.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Pemmaraju N, Kantarjian H, Sweet K, Wang
E, Senapati J, Wilson NR, Konopleva M, Frankel AE, Gupta V, Mesa R,
et al: North American blastic plasmacytoid dendritic cell neoplasm
consortium: Position on standards of care and areas of need. Blood.
141:567–578. 2023.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Arber DA, Orazi A, Hasserjian R, Thiele J,
Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M and Vardiman JW:
The 2016 revision to the World Health Organization classification
of myeloid neoplasms and acute leukemia. Blood. 127:2391–2405.
2016.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Morrison GM, Hopkins A, Knapp C, Kulkarni
R and Scopetta JP: Blastic plasmacytoid dendritic cell neoplasm
presenting as violaceous forehead plaque. Dermatol Online J 28:
10.5070/D328458522., 2022.
|
|
10
|
Azad F, Zhang J, Miranda CJ and Gravina M:
Venetoclax and azacitidine in the treatment of blastic plasmacytoid
dendritic cell neoplasm refractory to conventional therapy. Cureus.
14(e33109)2022.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Ma YQ, Sun Z, Li Y-M and Xu H: Blastic
plasmacytoid dendritic cell neoplasm: Two case reports. World J
Clin Oncol. 15:1207–1214. 2024.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Tao LL, Wen HT, Wang ZY, Cheng J and Zhao
L: Azacitidine maintenance therapy for blastic plasmacytoid
dendritic cell neoplasm allograft: A case report. World J Clin
Cases. 12:136–141. 2024.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Al-Alwan A, Khalid F, Vyas C, Sirpal V and
Bader H: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) in an
elderly female: A rare rash. J Community Hosp Intern Med Perspect.
13:79–81. 2023.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Alam H, Saeed N and Rashid A:
Indispensable role of immunophenotyping in diagnosing leukemic
phase of blastic plasmacytoid dendritic cell neoplasm without
cutaneous manifestation. Leuk Res Rep. 17(100317)2022.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Albiol N, Novelli S, Mozos A, Pratcorona
M, Martino R and Sierra J: Venetoclax in relapsed/refractory
blastic plasmacytoid dendritic cell neoplasm with central nervous
system involvement: A case report and review of the literature. J
Med Case Rep. 15(326)2021.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Aran BM, Duran J, Whittemore D and Gru AA:
A CD56- immunoblastoid variant of blastic plasmacytoid dendritic
cell neoplasm. J Cutan Pathol. 51:40–44. 2024.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Kumar PA, Ombada M, Pemmasani G, Tambe A,
Banki K and Gentile T: Liposomal daunorubicin and cytarabine, a
potential therapy for blastic plasmacytoid dendritic cell neoplasm.
J Investig Med High Impact Case Rep.
10(23247096221127114)2022.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Brett VE, Menguy S, Arcourt A, Bidet A,
Lechevalier A, Leguay T, Klein E, Garnache-Ottou F and Vial JP: An
unusual case of cytoplasmic CD3 expressing BPDCN supporting the
T-lineage origin of plasmacytoid dendritic cells. Cytometry B Clin
Cytom. 102:175–177. 2022.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Cai JW, Li MY, Wang WH, Shi HQ, Yang YH
and Chen JJ: Blastic plasmacytoid dendritic cell neoplasm in
Jinhua, China: Two case reports. World J Clin Cases. 12:5263–5270.
2024.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Castaño-Bonilla T, Mata R, Láinez-González
D, Gonzalo R, Castañón S, Pinta FJDdl, Blas C, López-Lorenzo JL and
Alonso-Domínguez JM: Spontaneous remission of blastic plasmacytoid
dendritic cell neoplasm: A case report. Medicina (Kaunas).
60(807)2024.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Chan G, Akintorin S, Luu M and Harter N:
Blastic plasmacytoid dendritic cell neoplasm with cutaneous
presentation: A case series in children. Pediatr Dermatol.
38:883–886. 2021.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Chen J, Zhang X, Ma L, Gao Y, Fu Z and Liu
M: 18F-FDG PET/CT findings in a patient with blastic
plasmacytoid dendritic cell neoplasm and post-transplant
lymphoproliferative disorder after hematopoietic stem cell
transplantation: a case report. Front Med (Lausanne).
10(1258310)2023.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Cianga VA, Dănăilă CD, Antohe I, Oană R,
Mențel M, Ivanov I, Dragoș L and Dăscălescu AS: A very rare
case of FLT3-D835 positive blastic plasmacytoid dendritic cell
neoplasm. Arch Clin Cases. 7:57–62. 2020.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Dang X, Zhou D, Meng L and Bi L: Blastic
plasmacytoid dendritic cell neoplasm with genetic mutations in
multiple epigenetic modifiers: A case report. J Int Med Res.
49(300060520982667)2021.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Dhakal P, Sy M, Sutamtewagul G, Mou E, Yu
N and Pemmaraju N: Overcoming Tagraxofusp-Erzs monotherapy
resistance in blastic plasmacytoid dendritic cell neoplasm (BPDCN)
in a real-world clinical setting. J Immunother Precis Oncol.
7:205–209. 2024.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Ding Y, Yang J and Lindsey K: Cytologic
features of blastic plasmacytoid dendritic cell neoplasm involving
liver: A case report and literature review. Diagn Cytopathol.
49:E80–E83. 2021.PubMed/NCBI View
Article : Google Scholar
|
|
27
|
Edjtemaei R, Ghanadan A and Ameli F:
Blastic plasmacytoid dendritic cell neoplasm of skin, a rare
dermatohematologic malignancy-A case report. Clin Case Rep.
12(e9398)2024.PubMed/NCBI View Article : Google Scholar
|
|
28
|
El Hussein S, Yabe M, Wang W, Pemmaraju N,
Loghavi S, Jelloul FZ, Fang H, Medeiros LJ, Burack WR, Evans AG, et
al: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) arising in
the setting of polycythemia vera (PV): An illustration of the
emerging role of flow cytometry analysis in monitoring progression
of myeloproliferative neoplasms. EJHaem. 3:954–957. 2022.PubMed/NCBI View
Article : Google Scholar
|
|
29
|
Fakhfakh Y, Aribia NB, Mnif S, Sannenna H,
Mnif H and Louati N: Blastic plasmacytoid dendritic cell neoplasm:
A diagnosis not to be missed, about three case reports. Tunis Med.
100:647–651. 2022.PubMed/NCBI
|
|
30
|
Fay CJ, Iriarte C, Moslehi D, Sheets AR
and LeBoeuf NR: Blastic plasmacytoid dendritic cell neoplasm
mimicking dermatomyositis. JAAD Case Rep. 39:70–73. 2023.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Fei F, Liedtke M and Silva O: Case report:
Mature plasmacytoid dendritic cell proliferation associated with a
lymphoid neoplasm. Front Oncol. 12(903113)2022.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Florescu AM, Sørensen ALT, Nielsen HV,
Tolnai D, Sjö LD, Larsen KL and Al-Karagholi MAM: Blastic
plasmacytoid dendritic cell neoplasm and cerebral toxoplasmosis: A
case report. BMC Neurol. 22(233)2022.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Gulati R, Abu-Salah A, Salous T and
Nassiri M: Relapse of tagraxofusp treated blastic plasmacytoid
dendritic cell neoplasm with loss of CD123 expression. J Hematop.
15:35–39. 2022.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Guo JH, Zhang HW, Wang L, Bai W and Wang
JF: Blastic plasmacytoid dendritic cell neoplasm with skin and bone
marrow involvement: Report of three cases. World J Clin Oncol.
9:10293–10299. 2021.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Hoffmann E, Böke S, De-Colle C, Lengerke
C, Niyazi KM and Gani C: Ulcerating skin lesions from blastic
plasmacytoid dendritic cell neoplasm responding to low-dose
radiotherapy-a case report and literature review. Strahlenther
Onkol. 200:908–915. 2024.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Hu X, Ediriwickrema A, Saleem A, Tan B,
Pemmaraju N and Mannis GN: CD38 and BCL2 expression guides
treatment with daratumumab and venetoclax in tagraxofusp-refractory
blastic plasmacytoid dendritic cell neoplasm (BPDCN) featuring
dynamic loss of CD123. Leuk Res. 139(107479)2024.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Jhajj B, Henrie R, El-Khalidy Y and Razavi
HM: A case of acute myeloid leukemia mimicking blastic plasmacytoid
dendritic cell neoplasm: Utility of the proposed upcoming WHO-5
diagnostic criteria. Case Rep Hematol. 2023(5014728)2023.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Jiang Y, Li Q, Yuan T, Jiang Y and Deng Q:
Case Report of Anti-CD123 chimeric antigen receptor T-cell therapy
followed by radiotherapy for a recurrence of blastic plasmacytoid
dendritic cell neoplasm after allogeneic hematopoietic stem cell
transplantation. Onco Targets Ther. 13:3425–3430. 2020.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Khan F, Hashmi F, Ghahramanyan N, Baloyan
E, Tamamyan G, Konopleva M, Pemmaraju M and Voskanyan A: Diagnosing
and treating blastic plasmacytoid dendritic cell neoplasm in a
resource-limited setting. Oncology (Williston Park). 38:104–106.
2024.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Khouloud M, Nader S, Ahlem B, Ines S,
Montacer H and Rayhan C: A rare case of Blastic plasmacytoid
dendritic cell neoplasm with gynecologic presentation. Leuk Res
Rep. 21(100462)2024.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Koerber RM, Held SAE, Vonnahme M, Feldmann
G, Wenzel J, Gütgemann I, Brossart P and Heine A: Blastic
plasmacytoid dendritic-cell neoplasia: A challenging case report. J
Cancer Res Clin Oncol. 148:743–748. 2022.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Kolerova A, Sergeeva I, Krinitsyna J,
Pronkina N, Sizikova S, Filimonov P and Kryuchkova I: Blastic
plasmacytoid dendritic cell neoplasm: Case report and literature
overview. Indian J Dermatol. 65:217–221. 2020.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Kosasih HJ, Healey G, Brennan MS,
Bjelosevic S, Sadras T, Jalud FB, Ibnat T, Ng AP, Mayoh C, Mao J,
et al: A novel MYB::PAIP1 oncogenic fusion in pediatric blastic
plasmacytoid dendritic cell neoplasm (BPDCN) is dependent on BCL2
expression and is sensitive to venetoclax. Hemasphere.
8(e1)2024.PubMed/NCBI View
Article : Google Scholar
|
|
44
|
Lee HJ, Park HM, Ki SY, Choi YD, Yun SJ
and Lim HS: Blastic plasmacytoid dendritic cell neoplasm of the
breast: A case report and review of the literature. Medicine
(Baltimore). 100(e25699)2021.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Liu F, Qi F, Zhang J, Tan Y and Zhang X:
Blastic plasmacytoid dendritic cell neoplasm with lung involvement
and cytopenia: A case report and a literature review. Clin Cosmet
Investig Dermatol. 16:2211–2216. 2023.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Mirgh S, Sharma A, Folbs B, Khushooc V,
Kapoorc J, Tejwanic N, Ahmedc R, Agrawald N, Choudharye PS, Mehta P
and Bhurani D: Daratumumab-based therapy after prior
Azacytidine-Venetoclax in an octagenerian female with BPDCN
(blastic plasmacytoid dendritic cell neoplasm)-a new perspective.
Leuk Lymphoma. 62:3039–3042. 2021.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Nagate Y, Nakaya A, Kamimura R, Hirose Y,
Nojima S, Fujita J, Kiyohara E and Shibayama H: Venetoclax combined
with azacytidine can be a first-line treatment option for elderly
blastic plasmacytoid dendritic cell neoplasm. Intern Med.
62:2547–2551. 2023.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Nasiri A, Lami A, Alhumaidi A, Madkhali A,
Althaqib A, Aljarwan N and Alkharras R: Blastic plasmacytoid
dendritic cell neoplasm: A case report. Cureus.
15(e37016)2023.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Nguyen K, Korsing S, Mansour Y and Meier
K: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) : A rare
hematologic neoplasm with frequent cutaneous involvement.
Dermatologie (Heidelb). 74:787–792. 2023.PubMed/NCBI View Article : Google Scholar : (In German).
|
|
50
|
Phusuphitchayanan P, Vejjabhinanta V,
Takpradit C, Sudtikoonaseth P, Chairatchaneeboon M, Kiatvichukul T
and Sukpanichnant S: A rare case of blastic plasmacytoid dendritic
cell neoplasm in a child mimicking lymphoma/leukemia cutis.
Dermatopathology (Basel). 9:321–326. 2022.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Razzeto A, Garala P, Amoozgar B, Daliparty
VM, Rehman F and Razzeto M: Blastic Plasmacytoid dendritic cell
neoplasm without cutaneous manifestation: A case report. Am J Case
Rep. 22(e932887)2021.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Sagou K, Ito M, Kawamura Y, Ukai S, Goto
M, Fukushima N, Ozeki K, Fukuyama R and Kohno A: Severe tumor lysis
syndrome during the induction therapy for the treatment of blastic
plasmacytoid dendritic cell neoplasm arising from
myelodysplastic/myeloproliferative neoplasms. Clin Case Rep.
9:878–882. 2021.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Sasaki Y, Murai S, Shiozawa E, Yamochi T
and Hattori N: Blastic plasmacytoid dendritic cell neoplasm in
long-term complete remission after venetoclax monotherapy. Cureus.
16(e52446)2024.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Shenjere P, Chasty R, Chaturvedi A, Dennis
MW, Ong A, Wiseman DH and Menasce LP: E-Cadherin expression in
blastic plasmacytoid dendritic cell neoplasms: An unrecognized
finding and potential diagnostic pitfall. Int J Surg Pathol.
29:289–293. 2021.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Shi J, Xu N, Niu Y, Jia SX, Yang CM and
Fang MY: Blastic plasmacytoid dendritic cell tumor treated with DVT
regimen: a case report and literature review. Zhonghua Xue Ye Xue
Za Zhi. 45:86–89. 2024.PubMed/NCBI View Article : Google Scholar : (In Chinese).
|
|
56
|
Sibai J, Chen R, Nabhani IA, Perusini MA
and Sibai H: Foot gangrene following Tagraxofusp treatment for
blastic plasmacytoid dendritic cell neoplasm: Case report. EJHaem.
3:1374–1376. 2022.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Suárez A, Soler N, Calderon A, Martinez B
and Piña M: Pediatric blastic plasmacytoid dendritic cell neoplasm,
clinical features and immunophenotype: A case report. Cureus.
15(e34549)2023.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Suzuki A, Abe S, Koyama K, Suzuki S, Nagao
M, Kobayashi M, Nomura J, Tsutsumi T, Takeda T, Oka Y, et al:
Spontaneous regression of blastic plasmacytoid dendritic cell
neoplasm following sepsis by Serratia marcescens: A case
report and literature review. Intern Med. 60:927–933.
2021.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Suzuki H, Takeshita M, Hirai R, Tanimura A
and Miwa A: Blastic plasmacytoid dendritic cell neoplasm developed
in chronic myeloid leukemia in molecular remission during a
four-year treatment-free interval after six years of dasatinib
treatment. Cureus. 16(e61944)2024.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Tirado CA, Reinartz J, Lapp K, Zhao D,
Nguyen AM and Stieglbauer K: Cytogenetic findings in a case of
blastic plasmacytoid dendritic cell neoplasm (BPDCN). J Assoc Genet
Technol. 46:5–13. 2020.PubMed/NCBI
|
|
61
|
Tong J, Aksenov S, Siegel BM, Wei L and
Rodgers WH: A rare case of blastic plasmacytoid dendritic cell
neoplasm occurred in postchemotherapy of breast cancer. Case Rep
Hematol. 2023(7573037)2023.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Wang X, Guo J, Liu Y, Zheng N, Xu S, Wu L,
Yuan R, Xue L and Li J: Venetoclax combined with azacitidine in
blastic plasmacytoid dendritic cell neoplasm: A case report and
comprehensive review on the current and future treatment. Front Med
(Lausanne). 11(1425833)2024.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Yoshioka K, Kurokawa R, Amemiya S,
Koyamaab H, Matsudab K, Hondab A, Kurokawab M, Shinozaki-Ushikuc A
and Abe O: Rapidly progressing blastic plasmacytoid dendritic cell
neoplasm causing diffuse skin thickening: A case report with
sequential computed tomography examinations. Radiol Case Rep.
16(29292933)2021.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Zhang L, Wang Y, Lu M, Shen M and Duan Z:
Patients with blastic plasmacytoid dendritic cell neoplasm in
pregnancy: A rare case report. Medicine (Baltimore).
101(e30622)2022.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Zhang X, Hsi ED, Crane GM and Cheng YW:
Biallelic TET2 mutations and canonical ASXL1 mutations are frequent
and cooccur in blastic plasmacytoid dendritic cell neoplasm
(BPDCN): An institutional experience and review of literature.
EJHaem. 4:236–240. 2023.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Khoury JD, Solary E, Abla O, Akkari Y,
Alaggio R, Apperley JF, Bejar R, Berti E, Busque L, Chan JKC, et
al: The 5th edition of the world health organization classification
of haematolymphoid tumours: Myeloid and histiocytic/dendritic
neoplasms. Leukemia. 36:1703–1719. 2022.PubMed/NCBI View Article : Google Scholar
|
|
67
|
Denker S, Künstner A, Schwarting J, Witte
HM, Bernard V, Stölting S, Lohneis P, Kusch K, Bubnoff Nv, Merz H,
et al: Clonal evolution and blastic plasmacytoid dendritic cell
neoplasm: malignancies of divergent hematopoietic lineages emerging
from a common founding clone. Leukemia. 38:1858–1861.
2024.PubMed/NCBI View Article : Google Scholar
|
|
68
|
Nervi B, Ramirez P, Rettig MP, Uy GL, Holt
MS, Ritchey JK, Prior JL, Piwnica-Worms D, Bridger G, Ley TJ and
DiPersio JF: Chemosensitization of acute myeloid leukemia (AML)
following mobilization by the CXCR4 antagonist AMD3100. Blood.
113:6206–6214. 2009.PubMed/NCBI View Article : Google Scholar
|
|
69
|
Crees ZD, Rettig MP and DiPersio JF:
Innovations in hematopoietic stem-cell mobilization: A review of
the novel CXCR4 inhibitor motixafortide. Ther Adv Hematol.
14(20406207231174304)2023.PubMed/NCBI View Article : Google Scholar
|
|
70
|
Zhao R, Liu J, Li Z, Zhang W, Wang F and
Zhang B: Recent advances in CXCL12/CXCR4 antagonists and nano-based
drug delivery systems for cancer therapy. Pharmaceutics.
14(1541)2022.PubMed/NCBI View Article : Google Scholar
|
|
71
|
Hosoba S, Harris WA, Lin KL and Waller EK:
Chemokine and lymph node homing receptor expression on pDC vary by
graft source. Oncoimmunology. 3(e958957)2014.PubMed/NCBI View Article : Google Scholar
|
|
72
|
Sweet K: Blastic plasmacytoid dendritic
cell neoplasm: Diagnosis, manifestations, and treatment. Curr Opin
Hematol. 27:103–107. 2020.PubMed/NCBI View Article : Google Scholar
|
|
73
|
Deotare U, Yee KWL, Le LW, Porwit A,
Tierens A, Musani R, Barth D, Torlakovic E, Schimmer A, Schuh AC,
et al: Blastic plasmacytoid dendritic cell neoplasm with leukemic
presentation: 10-Color flow cytometry diagnosis and HyperCVAD
therapy. Am J Hematol. 91:283–286. 2016.PubMed/NCBI View Article : Google Scholar
|
|
74
|
Bashir Q, Milton DR, Popat UR, Kebriaei P,
Hosing C, Khouri IF, Rezvani K, Nieto Y, Oran B, Srour SA, et al:
Allogeneic hematopoietic cell transplantation for patients with
blastic plasmacytoid dendritic cell neoplasm (BPDCN). Bone Marrow
Transplant. 57:51–56. 2022.PubMed/NCBI View Article : Google Scholar
|
|
75
|
Jen EY, Gao X, Li L, Zhuang L, Simoson NE,
Aryal B, Wang R, Przepiorka D, Shen YL, Leong R, et al: FDA
approval summary: Tagraxofusp-erzs For treatment of blastic
plasmacytoid dendritic cell neoplasm. Clin Cancer Res. 26:532–536.
2020.PubMed/NCBI View Article : Google Scholar
|
|
76
|
Shimony S, Luskin MR, Gangat N, LeBoeuf
NR, Feraco AM and Lane AA: Blastic plasmacytoid dendritic cell
neoplasm (BPDCN): 2025 Update on diagnosis, pathophysiology, risk
assessment, and management. Am J Hematol. 100:1408–1422.
2025.PubMed/NCBI View Article : Google Scholar
|
|
77
|
Yun S, Chan O, Kerr D, Vincelette ND,
Idrees A, Mo Q, Sweet K, Lancet JE, Kharfan-Dabaja MA, Zhang L and
Sokol L: Survival outcomes in blastic plasmacytoid dendritic cell
neoplasm by first-line treatment and stem cell transplant. Blood
Adv. 4:3435–3442. 2020.PubMed/NCBI View Article : Google Scholar
|
|
78
|
Pagano L, Valentini CG, Pulsoni A, Fisogni
S, Carluccio P, Mannelli F, Lunghi M, Pica G, Onida F, Cattaneo C,
et al: Blastic plasmacytoid dendritic cell neoplasm with leukemic
presentation: an Italian multicenter study. Haematologica.
98:239–246. 2013.PubMed/NCBI View Article : Google Scholar
|
|
79
|
Laribi K, Baugier De Materre A, Sobh M,
Cerroni L, Giovanna Valentini C, Aoki T, Suzuki R, Takeuchi K,
Frankel AE, Cota C, et al: Blastic plasmacytoid dendritic cell
neoplasms: Results of an international survey on 398 adult
patients. Blood Adv. 4:4838–4848. 2020.PubMed/NCBI View Article : Google Scholar
|
|
80
|
Taylor J, Haddadin M, Upadhyay VA, Grussie
E, Mehta-Shah N, Brunner AM, Jr AM, Lovitch SB, Dogan A, Fathi AT,
et al: Multicenter analysis of outcomes in blastic plasmacytoid
dendritic cell neoplasm offers a pretargeted therapy benchmark.
Blood. 134:678–687. 2019.PubMed/NCBI View Article : Google Scholar
|
|
81
|
Pemmaraju N, Wilson NR, Garcia-Manero G,
Sasaki K, Khoury JD, Jain N, Borthakur G, Ravandi F, Daver N, Kadia
T, et al: Characteristics and outcomes of patients with blastic
plasmacytoid dendritic cell neoplasm treated with frontline HCVAD.
Blood Adv. 6:3027–3035. 2022.PubMed/NCBI View Article : Google Scholar
|
|
82
|
Montero J, Stephansky J, Cai T, Griffin
GK, Cabal-Hierro L, Togami K, Hogdal LJ, Galinsky I, Morgan EA,
Aster JC, et al: Blastic plasmacytoid dendritic cell neoplasm is
dependent on BCL2 and sensitive to venetoclax. Cancer Discov.
7:156–164. 2017.PubMed/NCBI View Article : Google Scholar
|
|
83
|
DiNardo CD, Rausch CR, Benton C, Kadia T,
Jain N, Pemmaraju N, Daver N, Covert W, Marx KR, Mace M, et al:
Clinical experience with the BCL2-inhibitor venetoclax in
combination therapy for relapsed and refractory acute myeloid
leukemia and related myeloid malignancies. Am J Hematol.
93:401–407. 2018.PubMed/NCBI View Article : Google Scholar
|
|
84
|
Gangat N, Konopleva M, Patnaik MM, Jabbour
E, DiNardo C, Kadia T, Tefferi A and Pemmaraju N: Venetoclax and
hypomethylating agents in older/unfit patients with blastic
plasmacytoid dendritic cell neoplasm. Am J Hematol. 97:E62–E67.
2022.PubMed/NCBI View Article : Google Scholar
|
|
85
|
DiNardo CD, Jonas BA, Pullarkat V, Thirman
MJ, Garcia JS, Wei AH, Konopleva M, Döhner H, Letai A, Fenaux P, et
al: Azacitidine and venetoclax in previously untreated acute
myeloid leukemia. N Engl J Med. 383:617–629. 2020.PubMed/NCBI View Article : Google Scholar
|
|
86
|
Diebold K, Parker D, Worth S,
Espinoza-Gutarra M, Vachhani P, Bachiashvili K, Rangaraju S, Mohty
R, Bhatia and Jamy O: Outcomes with venetoclax 50 mg,
hypomethylating agents, and voriconazole or posaconazole in acute
myeloid leukemia. EJHaem. 6(e70049)2025.PubMed/NCBI View Article : Google Scholar
|
